pH-Dependent Polymer Coatings for GCC Agonist Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional oral formulations of guanylate cyclase C agonists face challenges such as side effects due to non-target tissue activity, degradation in the stomach, and inefficient delivery to specific regions of the gastrointestinal tract, limiting their effectiveness in treating gastrointestinal diseases like Crohn's disease and ulcerative colitis.
Innovation Solution
Development of novel formulations optimized for targeted delivery to specific regions of the gastrointestinal tract, using pH-dependent polymers and swellable polymers to protect the agonist from stomach acidity and ensure release at specific pH levels, minimizing side effects and enhancing therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional oral formulations are used, then the agonist can be administered orally, but degradation in the stomach occurs and delivery to specific regions is inefficient
Solution Approach 1:
The patent introduces pH-dependent polymers as intermediary substances that form a protective coating around the agonist. This coating acts as a mediator between the acidic stomach environment and the agonist, preventing degradation while allowing the agonist to reach the intestinal target region intact. The polymer coating is stable in acidic conditions but dissolves at higher pH levels in the intestine, releasing the active agonist at the correct location.
Solution Approach 2:
The patent utilizes pH-dependent polymers that change their solubility and structural properties based on pH changes along the gastrointestinal tract. The polymers remain insoluble and protective in the acidic stomach environment (low pH) but become soluble and release the agonist in the more neutral/alkaline intestinal environment (higher pH). This parameter change enables targeted delivery while maintaining stability during transit.
2Productivity
If the agonist is released in the stomach, then rapid absorption occurs, but side effects due to non-target tissue activity increase
Solution Approach 1:
The patent applies preliminary action by using pH-dependent polymers to delay the release of the agonist until it reaches the appropriate target region in the intestine. The protective coating is applied to the agonist before administration, and this coating intentionally remains intact during stomach transit, then dissolves at the correct location and time to release the agonist. This preliminary protective action prevents premature absorption and associated side effects.
Solution Approach 2:
The pH-dependent polymer serves as an intermediary that controls the timing and location of agonist release. It mediates between the need for rapid absorption (which would occur if the agonist were exposed to the stomach) and the need to avoid side effects (which requires delayed release). The polymer allows the system to achieve both by controlling the release kinetics based on pH conditions.
3Reliability
If the formulation targets specific gastrointestinal regions, then therapeutic efficacy improves, but formulation complexity increases
Solution Approach 1:
The patent achieves targeted delivery through parameter changes in the polymer coating properties. By selecting polymers with specific pH transition points, the formulation can be tailored to release the agonist at different locations along the gastrointestinal tract (stomach, small intestine, or colon) based on the pH gradient. This parameter-based targeting provides region-specific therapeutic efficacy without requiring complex mechanical delivery systems or multiple separate formulations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The targeted formulations reduce side effects, maintain higher agonist activity, and deliver effective doses to specific tissues, improving treatment outcomes for gastrointestinal disorders like Crohn's disease and ulcerative colitis by ensuring precise delivery and stability.
Implementation Method 1
The targeting material is chosen to provide for the pH-dependent release of the GCC agonist. In a preferred embodiment, the targeting material for a pH-dependent release formulation comprises a pH-dependent polymer that is stable in the low pH environment of the stomach (i.e., at pH 1-2) and begins to disintegrate at the pH of the proximal small intestine (pH 4.5-6) or distal ileum (pH 7-8).
Implementation Method 2
The targeting material is chosen to provide for controlled (time-dependent) release of the GCC agonist. In a preferred embodiment, the targeting material for a controlled release formulation comprises at least one swellable polymer.
Data Source
AI summary
The invention provides novel formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use in the treatment of gastrointestinal diseases and disorders, including gastrointestinal cancer. The GCC agonist formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.